PDE5A and pulmonary arterial hypertension: PAH requires early initiation of combination therapy with PDE5 inhibitors and endothelin receptor antagonists, additional prostacyclin analogues (e.g., Selexipag) or Riociguat where indicated, with consideration of Epoprostenol for patients with severe PAH.